← Browse by Condition
Medical Condition

intermediate risk non muscle invasive bladder cancer

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3
NCT06510374 Phase 3
Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Enrollment
454 pts
Location
United States, Canad...
Sponsor
Ferring Pharmaceuticals
View Trial →